MediWound Accelerates DFU Treatment with EIC Funds
Company Announcements

MediWound Accelerates DFU Treatment with EIC Funds

Mediwound (MDWD) has released an update.

MediWound Ltd. has secured a €16.25 million funding boost from the European Innovation Council Accelerator Program to fast-track the development of EscharEx, their promising treatment for diabetic foot ulcers. This substantial investment is set to advance the drug’s market launch by four years, highlighting the treatment’s potential to significantly impact patient care for a condition affecting millions. The funding encompasses a grant and an investment, with the latter’s terms under finalization, and underscores MediWound’s commitment to innovate in the field of non-surgical tissue repair and wound debridement.

For further insights into MDWD stock, check out TipRanks’ Stock Analysis page.

Related Articles
Christine BrownMDWD Upcoming Earnings Report: What to Expect?
TheFlyMediWound announces Phase II study evaluating EscharEx
TheFlyMediWound files to sell 1.45M ordinary shares for holders
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App